

# Kimberly J Van Zee

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2179325/publications.pdf>

Version: 2024-02-01

169  
papers

11,357  
citations

23500

58  
h-index

31759

101  
g-index

171  
all docs

171  
docs citations

171  
times ranked

8382  
citing authors

#	ARTICLE	IF	CITATIONS
1	Routine Opioid Prescriptions Are Not Necessary After Breast Excisional Biopsy or Lumpectomy Procedures. <i>Annals of Surgical Oncology</i> , 2021, 28, 303-309.	0.7	8
2	Intraoperative Ketorolac is Associated with Risk of Reoperation After Mastectomy: A Single-Center Examination. <i>Annals of Surgical Oncology</i> , 2021, 28, 5134-5140.	0.7	11
3	Patterns of invasive recurrence among patients originally treated for ductal carcinoma in situ by breast-conserving surgery versus mastectomy. <i>Breast Cancer Research and Treatment</i> , 2021, 186, 617-624.	1.1	8
4	Reply to: "Ketorolac Following Mastectomy: Is There an Increased Risk of Reoperation?" <i>Annals of Surgical Oncology</i> , 2021, 28, 777-778.	0.7	3
5	Postdischarge Nonsteroidal Anti-Inflammatory Drugs Are not Associated with Risk of Hematoma after Lumpectomy and Sentinel Lymph Node Biopsy with Multimodal Analgesia. <i>Annals of Surgical Oncology</i> , 2021, 28, 5507-5512.	0.7	4
6	ASO Visual Abstract: Post-Discharge Non-Steroidal Anti-Inflammatory Drugs Are Not Associated with Risk of Hematoma After Lumpectomy and Sentinel Lymph Node Biopsy with Multimodal Analgesia. <i>Annals of Surgical Oncology</i> , 2021, 28, 635-636.	0.7	0
7	Pilot Study of Anti-Th2 Immunotherapy for the Treatment of Breast Cancer-Related Upper Extremity Lymphedema. <i>Biology</i> , 2021, 10, 934.	1.3	30
8	Nodal Recurrence in Patients With Node-Positive Breast Cancer Treated With Sentinel Node Biopsy Alone After Neoadjuvant Chemotherapy" A Rare Event. <i>JAMA Oncology</i> , 2021, 7, 1851.	3.4	61
9	Microscopic Extracapsular Extension in Sentinel Lymph Nodes Does Not Mandate Axillary Dissection in Z0011-Eligible Patients. <i>Annals of Surgical Oncology</i> , 2020, 27, 1617-1624.	0.7	20
10	Cosmetic Outcomes Following Breast-Conservation Surgery and Radiation for Multiple Ipsilateral Breast Cancer: Data from the Alliance Z11102 Study. <i>Annals of Surgical Oncology</i> , 2020, 27, 4650-4661.	0.7	13
11	Atypical ductal hyperplasia bordering on DCIS on core biopsy is associated with higher risk of upgrade than conventional atypical ductal hyperplasia. <i>Breast Cancer Research and Treatment</i> , 2020, 184, 873-880.	1.1	8
12	Changing the Default: A Prospective Study of Reducing Discharge Opioid Prescription after Lumpectomy and Sentinel Node Biopsy. <i>Annals of Surgical Oncology</i> , 2020, 27, 4637-4642.	0.7	14
13	Prevalence and correlates of job and insurance problems among young breast cancer survivors within 18 months of diagnosis. <i>BMC Cancer</i> , 2020, 20, 432.	1.1	7
14	Treatment of Ductal Carcinoma In Situ: Considerations for Tailoring Therapy in the Contemporary Era. <i>Current Breast Cancer Reports</i> , 2020, 12, 98-106.	0.5	0
15	Comparison of Local Recurrence Risk Estimates After Breast-Conserving Surgery for DCIS: DCIS Nomogram Versus Refined Oncotype DX Breast DCIS Score. <i>Annals of Surgical Oncology</i> , 2019, 26, 3282-3288.	0.7	19
16	Impact of Age on Locoregional and Distant Recurrence After Mastectomy for Ductal Carcinoma In Situ With or Without Microinvasion. <i>Annals of Surgical Oncology</i> , 2019, 26, 4264-4271.	0.7	19
17	ASO Author Reflections: Does Genomic Testing of DCIS Provide Added Value? And Is It Worth the Cost?. <i>Annals of Surgical Oncology</i> , 2019, 26, 702-703.	0.7	0
18	ASO Author Reflections: Advising a Woman with Ductal Carcinoma In Situ Regarding Various Treatment Options" A Complex Decision. <i>Annals of Surgical Oncology</i> , 2019, 26, 4272-4273.	0.7	0

#	ARTICLE	IF	CITATIONS
19	Risk of Contralateral Breast Cancer in Women with Ductal Carcinoma In Situ Associated with Synchronous Ipsilateral Lobular Carcinoma In Situ. <i>Annals of Surgical Oncology</i> , 2019, 26, 4317-4325.	0.7	6
20	Ductal Carcinoma In Situ of the Breast. <i>Advances in Surgery</i> , 2019, 53, 21-35.	0.6	3
21	Long-Term Outcomes After Surgical Treatment of Malignant/Borderline Phyllodes Tumors of the Breast. <i>Annals of Surgical Oncology</i> , 2019, 26, 2136-2143.	0.7	30
22	Acupuncture for breast cancer-related lymphedema: a randomized controlled trial. <i>Breast Cancer Research and Treatment</i> , 2018, 170, 77-87.	1.1	27
23	Trajectories of quality of life following breast cancer diagnosis. <i>Breast Cancer Research and Treatment</i> , 2018, 169, 163-173.	1.1	28
24	Delay in radiotherapy is associated with an increased risk of disease recurrence in women with ductal carcinoma in situ. <i>Cancer</i> , 2018, 124, 46-54.	2.0	37
25	Surgical Treatment of Ductal Carcinoma In Situ. , 2018, , 171-192.		0
26	Controversies in the Treatment of Ductal Carcinoma in Situ. <i>Annual Review of Medicine</i> , 2017, 68, 197-211.	5.0	66
27	Society of Surgical Oncology Breast Disease Working Group Statement on Prophylactic (Risk-Reducing) Mastectomy. <i>Annals of Surgical Oncology</i> , 2017, 24, 375-397.	0.7	61
28	Outcomes for Women with Minimal-Volume Ductal Carcinoma In Situ Completely Excised at Core Biopsy. <i>Annals of Surgical Oncology</i> , 2017, 24, 3888-3895.	0.7	13
29	MRI and Prediction of Pathologic Complete Response in the Breast and Axilla after Neoadjuvant Chemotherapy for Breast Cancer. <i>Journal of the American College of Surgeons</i> , 2017, 225, 740-746.	0.2	77
30	Oncologic Outcomes After Treatment for MRI Occult Breast Cancer (pTON+). <i>Annals of Surgical Oncology</i> , 2017, 24, 3141-3147.	0.7	22
31	Contralateral Breast Cancer Risk in Women with Ductal Carcinoma In Situ: Is it High Enough to Justify Bilateral Mastectomy?. <i>Annals of Surgical Oncology</i> , 2017, 24, 2889-2897.	0.7	28
32	Confusion Over Differences in Registration and Randomization Criteria for the LORIS (Low-Risk DCIS) Trial: A Reply. <i>Annals of Surgical Oncology</i> , 2017, 24, 568-569.	0.7	2
33	Axillary Dissection and Nodal Irradiation Can Be Avoided for Most Node-positive Z0011-eligible Breast Cancers. <i>Annals of Surgery</i> , 2017, 266, 457-462.	2.1	90
34	Fibroepithelial Lesions in the Breast of Adolescent Females: A Clinicopathological Study of 54 Cases. <i>Breast Journal</i> , 2017, 23, 182-192.	0.4	31
35	Atypical Ductal Hyperplasia Bordering on Ductal Carcinoma In Situ. <i>International Journal of Surgical Pathology</i> , 2017, 25, 100-107.	0.4	31
36	Society of Surgical Oncology American Society for Radiation Oncology American Society of Clinical Oncology Consensus Guideline on Margins for Breast-Conserving Surgery With Whole-Breast Irradiation in Ductal Carcinoma in Situ. <i>Practical Radiation Oncology</i> , 2016, 6, 287-295.	1.1	135

#	ARTICLE	IF	CITATIONS
37	How Often Does Neoadjuvant Chemotherapy Avoid Axillary Dissection in Patients With Histologically Confirmed Nodal Metastases? Results of a Prospective Study. <i>Annals of Surgical Oncology</i> , 2016, 23, 3467-3474.	0.7	232
38	Impact of Age on Risk of Recurrence of Ductal Carcinoma In Situ: Outcomes of 2996 Women Treated with Breast-Conserving Surgery Over 30 Years. <i>Annals of Surgical Oncology</i> , 2016, 23, 2816-2824.	0.7	38
39	Age and Receptor Status Do Not Indicate the Need for Axillary Dissection in Patients with Sentinel Lymph Node Metastases. <i>Annals of Surgical Oncology</i> , 2016, 23, 3481-3486.	0.7	25
40	Do LORIS Trial Eligibility Criteria Identify a Ductal Carcinoma In Situ Patient Population at Low Risk of Upgrade to Invasive Carcinoma?. <i>Annals of Surgical Oncology</i> , 2016, 23, 3487-3493.	0.7	66
41	Margins in DCIS: Does Residual Disease Provide an Answer?. <i>Annals of Surgical Oncology</i> , 2016, 23, 3423-3425.	0.7	3
42	Society of Surgical Oncologyâ€”American Society for Radiation Oncologyâ€”American Society of Clinical Oncology Consensus Guideline on Margins for Breast-Conserving Surgery With Whole-Breast Irradiation in Ductal Carcinoma In Situ. <i>Journal of Clinical Oncology</i> , 2016, 34, 4040-4046.	0.8	211
43	Society of Surgical Oncologyâ€”American Society for Radiation Oncologyâ€”American Society of Clinical Oncology Consensus Guideline on Margins for Breast-Conserving Surgery with Whole-Breast Irradiation in Ductal Carcinoma In Situ. <i>Annals of Surgical Oncology</i> , 2016, 23, 3801-3810.	0.7	176
44	Women with Low-Risk DCIS Eligible for the LORIS Trial After Complete Surgical Excision: How Low Is Their Risk After Standard Therapy?. <i>Annals of Surgical Oncology</i> , 2016, 23, 4253-4261.	0.7	40
45	Treatment and Long-Term Risks for Patients With a Diagnosis of Ductal Carcinoma In Situ. <i>JAMA Oncology</i> , 2016, 2, 397.	3.4	7
46	Skin Flap Necrosis After Mastectomy With Reconstruction: A Prospective Study. <i>Annals of Surgical Oncology</i> , 2016, 23, 257-264.	0.7	121
47	Relationship Between Margin Width and Recurrence of Ductal Carcinoma In Situ. <i>Annals of Surgery</i> , 2015, 262, 623-631.	2.1	94
48	Reexcision â€” The Other Breast Cancer Epidemic. <i>New England Journal of Medicine</i> , 2015, 373, 568-569.	13.9	33
49	Trajectories of Posttraumatic Growth and Associated Characteristics in Women with Breast Cancer. <i>Annals of Behavioral Medicine</i> , 2015, 49, 650-659.	1.7	65
50	Trajectories of Depressive Symptoms Following Breast Cancer Diagnosis. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2015, 24, 1789-1795.	1.1	45
51	Use of Axillary Staging in the Management of Ductal Carcinoma In Situ. <i>JAMA Oncology</i> , 2015, 1, 332.	3.4	3
52	Decreasing Recurrence Rates for Ductal Carcinoma In Situ: Analysis of 2996 Women Treated with Breast-Conserving Surgery Over 30 Years. <i>Annals of Surgical Oncology</i> , 2015, 22, 3273-3281.	0.7	46
53	Long-term rates of ipsilateral breast tumor recurrence (IBTR) for women with ductal carcinoma in situ (DCIS) meeting LORIS trial eligibility criteria undergoing standard therapy.. <i>Journal of Clinical Oncology</i> , 2015, 33, 560-560.	0.8	0
54	Recurrence rates for ductal carcinoma in situ: Analysis of 2,996 patients treated with breast-conserving surgery over 30 years.. <i>Journal of Clinical Oncology</i> , 2015, 33, 32-32.	0.8	1

#	ARTICLE	IF	CITATIONS
55	Extent of Microinvasion in Ductal Carcinoma In Situ is not Associated with Sentinel Lymph Node Metastases. <i>Annals of Surgical Oncology</i> , 2014, 21, 3330-3335.	0.7	37
56	The Impact of Postmastectomy Radiotherapy on Two-Stage Implant Breast Reconstruction. <i>Plastic and Reconstructive Surgery</i> , 2014, 134, 588-595.	0.7	172
57	Local Relapse After Breast-Conserving Therapy for Ductal Carcinoma In Situ. <i>Cancer Journal (Sudbury, Tj ETQq1 1 0,784314 rgBT /Ov</i>	1.0	49
58	Perioperative Breast MRI Is Not Associated with Lower Locoregional Recurrence Rates in DCIS Patients Treated With or Without Radiation. <i>Annals of Surgical Oncology</i> , 2014, 21, 1552-1560.	0.7	50
59	Impact of Margin Assessment Method on Positive Margin Rate and Total Volume Excised. <i>Annals of Surgical Oncology</i> , 2014, 21, 86-92.	0.7	31
60	Axillary Dissection Can Be Avoided in the Majority of Clinically Node-Negative Patients Undergoing Breast-Conserving Therapy. <i>Annals of Surgical Oncology</i> , 2014, 21, 22-27.	0.7	99
61	Use of Established Nomograms to Predict Non-Sentinel Lymph Node Metastasis. <i>Current Breast Cancer Reports</i> , 2014, 6, 24-31.	0.5	2
62	Maastricht Delphi Consensus on Event Definitions for Classification of Recurrence in Breast Cancer Research. <i>Journal of the National Cancer Institute</i> , 2014, 106, .	3.0	73
63	Commentary on the Canadian National Breast Screening Study. <i>Annals of Surgical Oncology</i> , 2014, 21, 4397-4398.	0.7	0
64	Preoperative Breast MRI for Early-Stage Breast Cancer: Effect on Surgical and Long-Term Outcomes. <i>American Journal of Roentgenology</i> , 2014, 202, 1376-1382.	1.0	94
65	Radioactive Seed Localization Compared to Wire Localization in Breast-Conserving Surgery: Initial 6-Month Experience. <i>Annals of Surgical Oncology</i> , 2013, 20, 4121-4127.	0.7	90
66	Age-related longitudinal changes in depressive symptoms following breast cancer diagnosis and treatment. <i>Breast Cancer Research and Treatment</i> , 2013, 139, 199-206.	1.1	69
67	Blurry Boundaries: Do Epithelial Borderline Lesions of the Breast and Ductal Carcinoma In Situ Have Similar Rates of Subsequent Invasive Cancer?. <i>Annals of Surgical Oncology</i> , 2013, 20, 1302-1310.	0.7	7
68	Acupuncture in the treatment of upperâ€limb lymphedema. <i>Cancer</i> , 2013, 119, 2455-2461.	2.0	64
69	A Comparison of Breast Surgeon and Nomogram-Generated Risk Predictions of Sentinel and Non-Sentinel Node Metastases. <i>Journal of Cancer Therapy</i> , 2013, 04, 1-6.	0.1	0
70	Breast Ductal Carcinoma In Situ. <i>International Journal of Surgical Oncology</i> , 2012, 2012, 1-2.	0.3	0
71	Validation of a Nomogram for Predicting Risk of Local Recurrence for Ductal Carcinoma In Situ. <i>Journal of Clinical Oncology</i> , 2012, 30, 3143-3144.	0.8	7
72	Memorial Sloan-Kettering Cancer Center: Two Decades of Experience with Ductal Carcinoma In Situ of the Breast. <i>International Journal of Surgical Oncology</i> , 2012, 2012, 1-8.	0.3	2

#	ARTICLE	IF	CITATIONS
73	Explaining age-related differences in depression following breast cancer diagnosis and treatment. Breast Cancer Research and Treatment, 2012, 136, 581-591.	1.1	55
74	Axillary Node Staging for Microinvasive Breast Cancer: Is It Justified?. Annals of Surgical Oncology, 2012, 19, 3416-3421.	0.7	42
75	Papilloma Diagnosed at MRI-Guided Vacuum-Assisted Breast Biopsy: Is Surgical Excision Still Warranted?. American Journal of Roentgenology, 2012, 199, W512-W519.	1.0	27
76	Long-term outcomes in breast cancer patients undergoing immediate 2-stage expander/implant reconstruction and postmastectomy radiation. Cancer, 2012, 118, 2552-2559.	2.0	113
77	Is There a Low-Grade Precursor Pathway in Breast Cancer?. Annals of Surgical Oncology, 2012, 19, 1115-1121.	0.7	20
78	Are Nomograms for the Prediction of Non-Sentinel Lymph Node Status Obsolete?. Breast Diseases, 2011, 22, 15-17.	0.0	0
79	Ipsilateral Breast Tumor Recurrence After Breast-Conserving Surgery for Ductal Carcinoma in Situ. Annals of Surgery, 2011, 253, 1233-1234.	2.1	0
80	Intracystic Papillary Carcinoma of the Breast. American Journal of Surgical Pathology, 2011, 35, 1-14.	2.1	118
81	The effect of age in the outcome and treatment of older women with ductal carcinoma in situ. Breast, 2011, 20, 71-77.	0.9	13
82	Morbidity of Sentinel Node Biopsy: Relationship Between Number of Excised Lymph Nodes and Patient Perceptions of Lymphedema. Annals of Surgical Oncology, 2011, 18, 2866-2872.	0.7	48
83	A SEER-Medicare population-based study of lymphedema-related claims incidence following breast cancer in men. Breast Cancer Research and Treatment, 2011, 130, 301-306.	1.1	10
84	A Safety and Efficacy Pilot Study of Acupuncture for the Treatment of Chronic Lymphoedema. Acupuncture in Medicine, 2011, 29, 170-172.	0.4	38
85	Reply to U.K. Ballehaninna et al. Journal of Clinical Oncology, 2011, 29, e99-e99.	0.8	0
86	Reply to C. Mazouni et al. Journal of Clinical Oncology, 2011, 29, e45-e46.	0.8	2
87	Abstract 3139: Can PI3K/AKT pathway mutations predict for type of recurrence after conservative treatment for DCIS. , 2011, , .		0
88	The Influence of Margin Width and Volume of Disease Near Margin on Benefit of Radiation Therapy for Women With DCIS Treated With Breast-Conserving Therapy. Annals of Surgery, 2010, 251, 583-591.	2.1	40
89	Predictors of Completion Axillary Lymph Node Dissection in Patients With Immunohistochemical Metastases to the Sentinel Lymph Node in Breast Cancer. Annals of Surgical Oncology, 2010, 17, 1063-1068.	0.7	14
90	Tissue Expander Breast Reconstruction is Not Associated with an Increased Risk of Lymphedema. Annals of Surgical Oncology, 2010, 17, 2926-2932.	0.7	25

#	ARTICLE	IF	CITATIONS
91	Minimal Disease in the Sentinel Lymph Node: How to Best Measure Sentinel Node Micrometastases to Predict Risk of Additional Non-Sentinel Lymph Node Disease. <i>Annals of Surgical Oncology</i> , 2010, 17, 2909-2919.	0.7	21
92	Morbidity of Sentinel Node Biopsy in Breast Cancer: The Relationship Between the Number of Excised Lymph Nodes and Lymphedema. <i>Annals of Surgical Oncology</i> , 2010, 17, 3278-3286.	0.7	76
93	Stage IV breast cancer in the era of targeted therapy. <i>Cancer</i> , 2010, 116, 1226-1233.	2.0	165
94	Incidence and time course of bleeding after long-term amenorrhea after breast cancer treatment. <i>Cancer</i> , 2010, 116, 3102-3111.	2.0	127
95	Nomogram for Predicting the Risk of Local Recurrence After Breast-Conserving Surgery for Ductal Carcinoma In Situ. <i>Journal of Clinical Oncology</i> , 2010, 28, 3762-3769.	0.8	283
96	Postmastectomy intensity modulated radiation therapy following immediate expander-implant reconstruction. <i>Radiotherapy and Oncology</i> , 2010, 94, 319-323.	0.3	49
97	Concurrent lobular neoplasia increases the risk of ipsilateral breast cancer recurrence in patients with ductal carcinoma in situ treated with breast-conserving therapy. <i>Cancer</i> , 2009, 115, 1203-1214.	2.0	19
98	Validation of a Nomogram to Predict the Risk of Nonsentinel Lymph Node Metastases in Breast Cancer Patients with a Positive Sentinel Node Biopsy: Validation of the MSKCC Breast Nomogram. <i>Annals of Surgical Oncology</i> , 2009, 16, 1128-1135.	0.7	60
99	Mastectomy With Immediate Expander-Implant Reconstruction, Adjuvant Chemotherapy, and Radiation for Stage II-III Breast Cancer: Treatment Intervals and Clinical Outcomes. <i>International Journal of Radiation Oncology Biology Physics</i> , 2008, 70, 43-50.	0.4	51
100	Desmoid Tumors (Fibromatoses) of the Breast: A 25-Year Experience. <i>Annals of Surgical Oncology</i> , 2008, 15, 274-280.	0.7	104
101	Predicting Nonsentinel Node Metastases in Sentinel Node-Positive Breast Cancer: What Have We Learned, Can We Do Better, and Do We Need To?. <i>Annals of Surgical Oncology</i> , 2008, 15, 2998-3002.	0.7	10
102	MRI Identifies Otherwise Occult Disease in Select Patients with Paget Disease of the Nipple. <i>Journal of the American College of Surgeons</i> , 2008, 206, 316-321.	0.2	77
103	Predictive Models: The Art and the Science. <i>Breast Diseases</i> , 2008, 19, 118-119.	0.0	0
104	Prevalence of Lymphedema in Women With Breast Cancer 5 Years After Sentinel Lymph Node Biopsy or Axillary Dissection: Objective Measurements. <i>Journal of Clinical Oncology</i> , 2008, 26, 5213-5219.	0.8	530
105	Prevalence of Lymphedema in Women With Breast Cancer 5 Years After Sentinel Lymph Node Biopsy or Axillary Dissection: Patient Perceptions and Precautionary Behaviors. <i>Journal of Clinical Oncology</i> , 2008, 26, 5220-5226.	0.8	187
106	Doctor, What Are My Chances of Having a Positive Sentinel Node? A Validated Nomogram for Risk Estimation. <i>Journal of Clinical Oncology</i> , 2007, 25, 3670-3679.	0.8	283
107	A Declining Rate of Completion Axillary Dissection in Sentinel Lymph Node-positive Breast Cancer Patients Is Associated With the Use of a Multivariate Nomogram. <i>Annals of Surgery</i> , 2007, 245, 462-468.	2.1	126
108	Perpendicular Inked Versus Tangential Shaved Margins in Breast-Conserving Surgery: Does the Method Matter?. <i>Journal of the American College of Surgeons</i> , 2007, 204, 541-549.	0.2	47

#	ARTICLE	IF	CITATIONS
109	Can Surgical Oncologists Reliably Predict the Likelihood for Non-SLN Metastases in Breast Cancer Patients?. Annals of Surgical Oncology, 2007, 14, 615-620.	0.7	19
110	Eighteen Sensations After Breast Cancer Surgery: A 5-Year Comparison of Sentinel Lymph Node Biopsy and Axillary Lymph Node Dissection. Annals of Surgical Oncology, 2007, 14, 1653-1661.	0.7	50
111	Validating a Predictive Model for Presence of Additional Disease in the Non-Sentinel Lymph Nodes of a Woman with Sentinel Node Positive Breast Cancer. Annals of Surgical Oncology, 2007, 14, 2177-2178.	0.7	13
112	Outcomes for Women With Ductal Carcinoma-in-Situ and a Positive Sentinel Node: A Multi-Institutional Audit. Annals of Surgical Oncology, 2007, 14, 2911-2917.	0.7	66
113	Clinicopathologic Features and Long-Term Outcomes of 293 Phyllodes Tumors of the Breast. Annals of Surgical Oncology, 2007, 14, 2961-2970.	0.7	203
114	A 14-Year Retrospective Review of Angiosarcoma. Cancer Journal (Sudbury, Mass ), 2005, 11, 241-247.	1.0	350
115	Utility of Breast Magnetic Resonance Imaging in Patients With Occult Primary Breast Cancer. Annals of Surgical Oncology, 2005, 12, 1045-1053.	0.7	121
116	Predicting Nonsentinel Node Status After Positive Sentinel Lymph Biopsy for Breast Cancer: Clinicians Versus Nomogram. Annals of Surgical Oncology, 2005, 12, 654-659.	0.7	211
117	Can the Memorial Sloan-Kettering Cancer Center Nomogram Predict the Likelihood of Nonsentinel Lymph Node Metastases in Breast Cancer Patients in The Netherlands?. Annals of Surgical Oncology, 2005, 12, 1066-1072.	0.7	108
118	Mri-Guided Needle Localization. , 2005, , 23-27.		0
119	Total Mastectomy. , 2005, , 79-91.		0
120	Eighteen Sensations After Breast Cancer Surgery: A Two-Year Comparison of Sentinel Lymph Node Biopsy and Axillary Lymph Node Dissection. Oncology Nursing Forum, 2004, 31, 691-698.	0.5	36
121	Minimally invasive breast surgery. Journal of the American College of Surgeons, 2004, 199, 961-975.	0.2	14
122	A Prospective Analysis of the Effect of Blue-Dye Volume on Sentinel Lymph Node Mapping Success and Incidence of Allergic Reaction in Patients With Breast Cancer. Annals of Surgical Oncology, 2004, 11, 535-541.	0.7	67
123	A tool for predicting breast carcinoma mortality in women who do not receive adjuvant therapy. Cancer, 2004, 101, 2509-2515.	2.0	42
124	A Nomogram for Predicting the Likelihood of Additional Nodal Metastases in Breast Cancer Patients With a Positive Sentinel Node Biopsy. Annals of Surgical Oncology, 2003, 10, 1140-1151.	0.7	747
125	The accuracy of sentinel lymph node biopsy in multicentric and multifocal invasive breast cancers. Journal of the American College of Surgeons, 2003, 197, 529-535.	0.2	127
126	MR Imaging Findings in the Contralateral Breast of Women with Recently Diagnosed Breast Cancer. American Journal of Roentgenology, 2003, 180, 333-341.	1.0	287



#	ARTICLE	IF	CITATIONS
127	Fast MRI-Guided Vacuum-Assisted Breast Biopsy:Initial Experience. American Journal of Roentgenology, 2003, 181, 1283-1293.	1.0	134
128	Point: Sentinel Lymph Node Biopsy Is Indicated for Patients With DCIS. Journal of the National Comprehensive Cancer Network: JNCCN, 2003, 1, 199-206.	2.3	22
129	One Operation After Percutaneous Diagnosis of Nonpalpable Breast Cancer. American Journal of Roentgenology, 2002, 178, 673-679.	1.0	41
130	Isosulfan Blue Dye Reactions During Sentinel Lymph Node Mapping for Breast Cancer. Anesthesia and Analgesia, 2002, 95, 385-388.	1.1	94
131	Isosulfan Blue Dye Reactions During Sentinel Lymph Node Mapping for Breast Cancer. Anesthesia and Analgesia, 2002, 95, 385-388.	1.1	196
132	Eighteen Sensations After Breast Cancer Surgery: A Comparison of Sentinel Lymph Node Biopsy and Axillary Lymph Node Dissection. Oncology Nursing Forum, 2002, 29, 651-659.	0.5	43
133	Breast imaging: a breast surgeon's perspective. Radiologic Clinics of North America, 2002, 40, 517-520.	0.9	0
134	Reoperative sentinel lymph node biopsy. Journal of the American College of Surgeons, 2002, 195, 167-172.	0.2	120
135	Sensory morbidity after sentinel lymph node biopsy and axillary dissection: A prospective study of 233 women. Annals of Surgical Oncology, 2002, 9, 654-662.	0.7	122
136	Sentinel Lymph Node Drainage in Multicentric Breast Cancers. Breast Journal, 2002, 8, 356-361.	0.4	43
137	Sensory morbidity after sentinel lymph node biopsy and axillary dissection: A prospective study of 233 women. , 2002, 9, 654.		12
138	Intradermal Isotope Injection: A Highly Accurate Method of Lymphatic Mapping in Breast Carcinoma. Annals of Surgical Oncology, 2001, 8, 20-24.	0.7	90
139	Is It Really Duct Carcinoma In Situ?. Annals of Surgical Oncology, 2001, 8, 617-617.	0.7	23
140	Oral Gossypol in the Treatment of Patients with Refractory Metastatic Breast Cancer: A Phase I/II Clinical Trial. Breast Cancer Research and Treatment, 2001, 66, 239-248.	1.1	189
141	Genetic Alterations of the p14ARF-hdm2-p53 Regulatory Pathway in Breast Carcinoma. Breast Cancer Research and Treatment, 2001, 65, 225-232.	1.1	23
142	Expression of E2F-1 and E2F-4 is reduced in primary and metastatic breast carcinomas*. Breast Cancer Research and Treatment, 2001, 69, 115-122.	1.1	33
143	Molecular analysis of the INK4A and INK4B gene loci in human breast cancer cell lines and primary carcinomas. Cancer Genetics and Cytogenetics, 2001, 125, 131-138.	1.0	18
144	Comprehensive review of the management of internal mammary lymph node metastases in breast cancer 1 1No competing interests declared.. Journal of the American College of Surgeons, 2001, 193, 547-555.	0.2	84

#	ARTICLE	IF	CITATIONS
145	Bracketing Wires for Preoperative Breast Needle Localization. American Journal of Roentgenology, 2001, 177, 565-572.	1.0	89
146	Intradermal Isotope Injection: A Highly Accurate Method of Lymphatic Mapping in Breast Carcinoma. , 2001, 8, 20.		6
147	In microdissected ductal carcinoma in situ, HER-2/neu amplification, but not p53 mutation, is associated with high nuclear grade and comedo histology. Cancer, 2000, 89, 2153-2160.	2.0	37
148	Sentinel lymphadenectomy accurately predicts nodal status in T2 breast cancer11No competing interests declared.. Journal of the American College of Surgeons, 2000, 191, 593-599.	0.2	72
149	Chest wall resection for locally recurrent breast cancer: Is it worthwhile?. Journal of Thoracic and Cardiovascular Surgery, 2000, 119, 420-428.	0.4	61
150	Magnetic Resonance Imaging Facilitates Breast Conservation for Occult Breast Cancer. Annals of Surgical Oncology, 2000, 7, 411-415.	0.7	162
151	Sentinel Lymph Node Biopsy: Is It Indicated in Patients With High-Risk Ductal Carcinoma-In-Situ and Ductal Carcinoma-In-Situ With Microinvasion?. Annals of Surgical Oncology, 2000, 7, 636-642.	0.7	304
152	Evaluation of Pectoralis Major Muscle in Patients with Posterior Breast Tumors on Breast MR Images: Early Experience. Radiology, 2000, 214, 67-72.	3.6	105
153	Are breast cancer patients at increased risk for colorectal adenomas and cancer: Effect of family history and age. Gastroenterology, 2000, 118, A44.	0.6	0
154	Issues of Regret in Women With Contralateral Prophylactic Mastectomies. Annals of Surgical Oncology, 1999, 6, 546-552.	0.7	162
155	Six-Year Follow-Up of Patients With Microinvasive, T1a, and T1b Breast Carcinoma. Annals of Surgical Oncology, 1999, 6, 591-598.	0.7	34
156	Long term follow-up of women with ductal carcinoma in situ treated with breast-conserving surgery. , 1999, 86, 1757-1767.		114
157	Hypomethylation and increased gene expression of p16INK4a in primary and metastatic breast carcinoma as compared to normal breast tissue. Oncogene, 1998, 16, 2723-2727.	2.6	43
158	Preoperative galactography increases the diagnostic yield of major duct excision for nipple discharge. , 1998, 82, 1874-1880.		94
159	Volume of resection in patients treated with breast conservation for ductal carcinoma in situ. Annals of Surgical Oncology, 1998, 5, 757-763.	0.7	25
160	Incidence of axillary lymph node metastases in T1a and T1b breast carcinoma. Annals of Surgical Oncology, 1998, 5, 23-27.	0.7	56
161	Patient regrets after bilateral prophylactic mastectomy. Annals of Surgical Oncology, 1998, 5, 603-606.	0.7	107
162	Preoperative galactography increases the diagnostic yield of major duct excision for nipple discharge. Cancer, 1998, 82, 1874-80.	2.0	12

#	ARTICLE	IF	CITATIONS
163	Microsatellite instability in breast cancer. <i>Annals of Surgical Oncology</i> , 1997, 4, 310-315.	0.7	17
164	Absence of p16 gene (CDKN2) deletions in microdissected primary breast carcinoma specimens. <i>Annals of Surgical Oncology</i> , 1997, 4, 416-420.	0.7	8
165	Predictors of intrusive thoughts and avoidance in women with family histories of breast cancer. <i>Annals of Behavioral Medicine</i> , 1997, 19, 362-369.	1.7	131
166	Ductal carcinoma in situ of the breast: Progress and controversy. <i>Current Problems in Surgery</i> , 1996, 33, 555-600.	0.6	18
167	The role of bactericidal/permeability-increasing protein in the treatment of primate bacteremia and septic shock. <i>Journal of Clinical Immunology</i> , 1994, 14, 120-133.	2.0	28
168	Cachexia and the acute-phase protein response in inflammation are regulated by interleukin-6. <i>European Journal of Immunology</i> , 1993, 23, 1889-1894.	1.6	148
169	Comparison of Peripheral Blood Leukocyte Kinetics After Live <i>Escherichia coli</i> , Endotoxin, or Interleukin-1 Administration Studies Using a Novel Interleukin-1 Receptor Antagonist. <i>Annals of Surgery</i> , 1993, 218, 79-90.	2.1	30